Skip to main content

UTI Treatment Antibiotics

Category: Pharmacology > Infection & Prophylaxis

Overview​

Antibiotic treatment of urinary tract infection is stratified by anatomic site (cystitis versus pyelonephritis), host factors (uncomplicated versus complicated), and the presence of sepsis, drug-resistant organisms, or device-associated infection. The reconstructive urologist's UTI population skews toward the complicated end (neurogenic bladders, indwelling catheters, continent diversions, prosthetic devices, post-reconstruction anatomy).

Mechanism of Action​

Antibiotic classes used for UTI work through the following broad mechanisms:

ClassMechanismGU-relevant examples
NitrofuranMulti-target enzyme damage (DNA, ribosomal, cell-wall biosynthesis)Nitrofurantoin
Sulfonamide + dihydrofolate reductase inhibitorDual folate-pathway inhibitionTMP-SMX
Phosphonic acidBlocks peptidoglycan synthesis (MurA)Fosfomycin
FluoroquinoloneDNA gyrase + topoisomerase IV inhibitionCiprofloxacin, levofloxacin
β-lactamCell-wall synthesis (transpeptidase)Cephalexin, cefpodoxime, cefazolin, cefepime, ceftriaxone, piperacillin-tazobactam, carbapenems
β-lactam + β-lactamase inhibitorAdds protection against β-lactamasesAmoxicillin-clavulanate, piperacillin-tazobactam, ceftolozane-tazobactam, ceftazidime-avibactam
Aminoglycoside30S ribosomal inhibitionGentamicin, amikacin, tobramycin
Tetracycline30S ribosomal inhibitionDoxycycline (chronic prostatitis)
PolymyxinCell-membrane disruptionColistin (rescue for MDR Pseudomonas/Enterobacterales)
Siderophore cephalosporinIron-dependent cell-wall uptakeCefiderocol

Agents in This Class​

Oral agents for bladder-limited infection​

AgentKey featuresTypical cystitis dose
Nitrofurantoin (monohydrate/macrocrystals)Urine-concentrated; minimal systemic / microbiome impact; renal restrictions differ between current guidance and US labeling; see precautions; pulmonary fibrosis with long-term use100 mg PO BID × 5 days[30]
TMP-SMX (trimethoprim-sulfamethoxazole)Broad coverage; empiric first-choice use requires known local E. coli resistance <20%; G6PD caution[30]160/800 mg PO BID × 3 days
Fosfomycin (trometamol)Single-dose oral; useful in ESBL; lower efficacy than nitrofurantoin in head-to-head RCT; not for pyelonephritis3 g PO × 1
Pivmecillinam (Pivya)FDA-approved 2024 for uncomplicated UTI in women ≥18 y due to susceptible E. coli, P. mirabilis, S. saprophyticus; long European track record[17]185 mg PO TID × 3–7 days (US label)
Gepotidacin (Blujepa)First-in-class triazaacenaphthylene dual-target topoisomerase inhibitor; FDA-approved 2025 for uncomplicated UTI in females ≥12 y and ≥40 kg; non-inferior to nitrofurantoin in EAGLE-2 / EAGLE-3 phase 3 trials[18][25]1,500 mg PO BID × 5 days

Second-line oral / step-down agents​

AgentKey features
Cephalexinβ-lactam for uncomplicated UTI; short duration; no ESBL coverage
CefpodoximeOral 3rd-gen cephalosporin; not reliable for ESBL infections
Amoxicillin-clavulanateβ-lactamase-inhibitor combo; EAU does not recommend empirical cystitis use because of ecological collateral damage, though selected cases may be appropriate[30]; selected susceptible non-ESBL urinary-source infections may permit oral step-down[6]; not suggested for ESBL-producing Enterobacterales bloodstream infection[8]
CiprofloxacinWorkhorse fluoroquinolone; Pseudomonas coverage; boxed and other serious warnings; see precautions
LevofloxacinOnce-daily; similar profile to cipro
DoxycyclinePathogen-directed prostatitis, especially susceptible intracellular pathogens; not a blanket substitute for fluoroquinolones

IV agents (complicated UTI, urosepsis)​

AgentRole
CeftriaxoneIV workhorse; not reliable for ESBL infections; penetrates prostate/CSF
Cefepime4th-gen cephalosporin; Pseudomonas coverage; AmpC stability
Piperacillin-tazobactamBroad gram-negative including Pseudomonas; not preferred for ESBL bacteremia
Meropenem / Ertapenem / Imipenem-cilastatinCarbapenems; reserve for ESBL, multidrug-resistant organisms
AztreonamMonobactam; generally low cross-reactivity, but a ceftazidime allergy needs specific assessment because of the shared side chain[33]
Aminoglycosides (gentamicin, amikacin)Single-dose therapy can be used for selected cystitis; cUTI requires a full treatment plan with renal dosing and toxicity monitoring

Agents for resistant organisms (check regulatory status)​

AgentPrimary indication[8][9]
Ceftolozane-tazobactamDifficult-to-treat Pseudomonas aeruginosa; ESBL
Ceftazidime-avibactamKPC and OXA-48 carbapenem-resistant Enterobacterales; DTR Pseudomonas
Meropenem-vaborbactamKPC carbapenem-resistant Enterobacterales
Imipenem-cilastatin-relebactamDTR Pseudomonas; KPC CRE
CefiderocolSusceptibility-guided option for resistant gram-negative infection; organism/site-specific guidance is needed, particularly for Acinetobacter and Stenotrophomonas
Cefepime-taniborbactam (investigational)CERTAIN-1 found higher composite success than meropenem in the prespecified population with organisms susceptible to both drugs.[20]
Cefepime-enmetazobactamFor ESBL-producing Enterobacterales cUTI when susceptible TMP-SMX or fluoroquinolones cannot be used, IDSA 2026 lists cefepime-enmetazobactam as a preferred IV option. In the Kaye 2022 cUTI/pyelonephritis RCT, combined clinical cure and microbiologic eradication at day 14 was higher than with piperacillin-tazobactam in the overall mixed-pathogen analysis set with a baseline gram-negative pathogen not resistant to either treatment, not the ESBL-E subgroup (273/345 versus 196/333). It is a potential carbapenem-sparing option, without a direct carbapenem comparison.[19][8]
PlazomicinAminoglycoside FDA-approved for adult cUTI, including pyelonephritis, from designated susceptible organisms when alternatives are limited; CRE activity requires isolate susceptibility testing and is absent with 16S rRNA methyltransferase producers. Boxed risks include nephrotoxicity, ototoxicity, neuromuscular blockade and fetal harm; assess creatinine clearance daily and use therapeutic drug monitoring for cUTI when CrCl is ≥15 and <90 mL/min.[8][48]

Indications in Reconstructive Urology​

Uncomplicated Cystitis​

Scope: The traditional short-course evidence chiefly concerns bladder-limited infection in nonpregnant women. Current IDSA classification also recognizes bladder-confined infection in afebrile men; menopausal status alone does not make an infection complicated. Catheter-associated infection, systemic illness and prostatic involvement require separate assessment.[6][8]

Common oral options (select by syndrome, susceptibility and local guidance):[1][2][3][4][17]

  • Nitrofurantoin 100 mg PO BID × 5 days (guideline regimen; the Macrobid label states 7 days)[30][31]
  • TMP-SMX 160/800 mg PO BID × 3 days (if local resistance <20%)[30]
  • Fosfomycin 3 g PO × 1 dose .[30] A head-to-head RCT found lower clinical resolution than a five-day nitrofurantoin regimen; it used nitrofurantoin 100 mg TID, rather than the commonly prescribed monohydrate or macrocrystal BID schedule.[32]
  • Pivmecillinam 185 mg PO TID × 3–7 days (US label) (Pivya, FDA-approved 2024); EAU 2026 lists 400 mg TID for 3–5 days[17][30]

Newly FDA-approved option (first-in-class):

  • Gepotidacin 1,500 mg PO BID × 5 days (Blujepa). Non-inferior to nitrofurantoin in EAGLE-2 and EAGLE-3 for composite therapeutic success (complete symptom resolution plus microbiologic success without other systemic antibiotics) at day 10–13 among treated patients with nitrofurantoin-susceptible qualifying uropathogens; EAGLE-3 was superior (162/277 [58.5%] versus 115/264 [43.6%]); FDA-approved 2025 for females ≥12 y and ≥40 kg.[18][25] Take after a meal; it prolongs QTc, so avoid it with QTc-prolonging drugs or in patients with prior QTc prolongation or relevant cardiac disease. Also avoid strong CYP3A4 inhibitors or inducers, severe renal impairment (eGFR <30 mL/min), or severe hepatic impairment.[18][25]

Not recommended as first-line:

  • Fluoroquinolones. Excess adverse effects and resistance in the uncomplicated setting; EAU 2026 advises against fluoroquinolones or aminopenicillins for cystitis ; its alternatives include cefadroxil 500 mg BID for 3 days, and trimethoprim 200 mg BID × 5 days or TMP-SMX 160/800 mg BID × 3 days, the latter two only where local E. coli resistance is below 20%[30]
  • β-lactams (amoxicillin-clavulanate, cefpodoxime). EAU does not recommend empirical use for cystitis because of ecological collateral damage, but allows selected cases.[30]

Network meta-analysis of duration (Kim 2020 Lancet ID, 61 RCTs, 20,780 women): a 3-day course of a third- or fourth-generation fluoroquinolone performed like a single dose, and 5- or 7-day pivmecillinam performed like 3 days, so shorter courses were adequate for those agents. Single-dose co-trimoxazole and second-generation quinolones were less effective than 3 days. Evidence for shortening other agents was of low quality.[21] The WikiGuidelines consensus gives clear duration recommendations of 5 days for nitrofurantoin, 3 days for TMP-SMX and pivmecillinam, a single dose for oral fosfomycin and 5 days for gepotidacin.[7]

E. coli causes approximately 75% of uncomplicated cystitis.[1][3][4]

Uncomplicated UTI in men​

Obtain a urine culture and assess for fever, retention and prostatic involvement. Seven-day TMP-SMX or fluoroquinolone courses have evidence in selected afebrile men. EAU 2026 suggests TMP-SMX 160/800 mg BID for 7 days in its regimen table, and recommends pivmecillinam or nitrofurantoin for empirical treatment of cystitis in younger men.[30] It limits nitrofurantoin to men in whom prostatic involvement has been reliably excluded and notes that evidence on its optimal duration is lacking.[3][30]

The updated 2026 French infectious-disease society (SPILF) guideline on male UTI frames the initial evaluation by age band: a younger man warrants exclusion of a sexually transmitted infection (chlamydia, gonorrhea) by history, examination and urinalysis, with urethral swab or NAAT testing when one is suspected, while an older man more often has bladder outlet obstruction from benign prostatic hyperplasia and overlapping chronic prostatitis or asymptomatic bacteriuria as confounders. A postvoid residual and prostate examination are reasonable additions to this workup in an older man, alongside the AUA Symptom Score already used to evaluate voiding symptoms attributed to BPH.[12][36][37]

Acute Uncomplicated Pyelonephritis​

Oral fluoroquinolone regimens (ciprofloxacin when local resistance <10%):[30]

  • Ciprofloxacin 500 mg PO BID × 7 days[30] or
  • Levofloxacin 750 mg PO daily × 5 days[43]

TMP-SMX 160/800 mg PO BID is an option when susceptible.[30] Fourteen days is the older regimen; IDSA 2025 suggests seven days of effective non-fluoroquinolone therapy in clinically improving cUTI or pyelonephritis, with important exclusions below.[23] EAU 2026 makes short-course fluoroquinolones first-line for outpatient pyelonephritis (Strong; ciprofloxacin 500–750 mg BID × 7 days when local fluoroquinolone resistance is <10%, or levofloxacin 500 mg daily × 5 days, with a high-dose 500 mg BID option).[30] Oral alternatives are TMP-SMX 160/800 mg BID × 14 days, cefpodoxime 200 mg BID × 10 days or ceftibuten 400 mg daily × 10 days, each preceded by one dose of a long-acting parenteral agent such as ceftriaxone when susceptibility is unknown.[30] EAU advises against nitrofurantoin, oral fosfomycin and pivmecillinam for pyelonephritis , and at least two weeks of treatment, preferably a fluoroquinolone, in men with febrile UTI.[2][23][30]

If empiric oral fluoroquinolone coverage is unreliable, an initial long-acting parenteral agent may be needed even in a stable outpatient; severe illness or inability to tolerate PO requires a broader IV plan.[5]

Examples of initial IV agents (adjust to severity, organism risk and renal function):

  • Ceftriaxone 1–2 g IV daily
  • Piperacillin-tazobactam 3.375 g IV q6h
  • Fluoroquinolone IV (ciprofloxacin 400 mg IV q12h[30] or levofloxacin 750 mg IV daily[8])
  • Aminoglycoside initial dose for selected cUTI/pyelonephritis in the IDSA AMR guidance (gentamicin 7 mg/kg IV or amikacin 15 mg/kg IV); base further dosing on pharmacokinetics and reassess oral transition once susceptibility is known.[8]

Transition to oral therapy once susceptibility results available and clinically improving. EAU 2026 lists ciprofloxacin 400 mg IV BID, cefotaxime 2 g IV TID, and ceftriaxone 2 g IV daily (2 g IV BID high dose) in its parenteral pyelonephritis table; the levofloxacin entry instead prints 500 mg oral daily (500 mg oral BID high dose). Second-line agents are cefepime, piperacillin-tazobactam 4.5 g TID, gentamicin 6–7 mg/kg daily, or amikacin 25–30 mg/kg daily.[30]

Complicated UTI / Urosepsis​

In patients with neurogenic bladder, catheterization, diversion, stricture, obstruction, prosthetic devices, transplant or older age, classify UTI by symptoms and severity before choosing therapy. For suspected systemic UTI, obtain a urine culture; add blood cultures for sepsis, severe illness or S. aureus bacteriuria.[30]

IDSA 2025 classification: pyelonephritis and febrile or bacteremic UTI qualify as cUTI, as does symptomatic UTI with a long-term indwelling catheter, stent or nephrostomy; age or a chronic lower-tract abnormality alone does not define cUTI, and bacterial prostatitis is outside this guideline's treatment questions.[6][15]

The AUA/CUA/SUFU 2025 guideline defines "complicated" differently: any anatomic or functional urinary-tract abnormality (stones, diverticulum, neurogenic LUTD), immunocompromise, an indwelling catheter or stent, or systemic symptoms takes a patient out of its "uncomplicated" category, regardless of whether infection has extended beyond the bladder.[6][24] A patient with a neurogenic bladder or a ureteral stent and isolated cystitis symptoms is therefore complicated by AUA criteria but may still be uncomplicated by IDSA criteria.[6][24]

IDSA 2025 four-step empiric framework:[6]

  1. Assess severity of illness (from septic shock to sepsis to stable)
  2. Assess resistance risk factors (prior ESBL or MDR organism, recent antibiotic exposure, catheter, transplant, prior healthcare contact)
  3. Assess patient-specific considerations (allergy, renal function, drug interactions)
  4. For sepsis assumed to be caused by complicated UTI, consider a local, recent, population-relevant antibiogram to tailor empiric antibiotic choice .[6] The targets below are model-based considerations when an antibiogram is used.
ScenarioModel-based susceptibility target when using an antibiogramOptions
cUTI with septic shock≥90% local susceptibility[6]3rd / 4th-gen cephalosporin, carbapenem, piperacillin-tazobactam, or fluoroquinolone
cUTI with sepsis (no shock)≥80% local susceptibility[6]3rd / 4th-gen cephalosporin, carbapenem, piperacillin-tazobactam, or fluoroquinolone
cUTI without sepsisNo specific antibiogram threshold recommendation3rd / 4th-gen cephalosporin, piperacillin-tazobactam, or fluoroquinolone — prefer narrower options when appropriate; prior cultures or severe resistance may justify a carbapenem

De-escalation: once susceptibility known, narrow to the most targeted effective agent and, where feasible, switch to oral step-down therapy.

IV-to-oral transition (IDSA 2025): switch when the patient is clinically improving, tolerating PO, and has an effective oral option, including patients with gram-negative bacteremia provided source control is achieved.[22]

Duration (IDSA 2025):[23]

  • cUTI (including pyelonephritis), improving on effective therapy: IDSA 2025 conditionally suggests 5–7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone; EAU 2026 advises at least 14 days for men with febrile UTI. In a 240-man randomized ofloxacin trial, six-week composite success (negative culture, no fever or retreatment) was 64/115 after 7 days versus 97/125 after 14 days.[23][30][49]
  • cUTI with gram-negative bacteremia: 7 days in patients improving on effective therapy

Count duration from the first effective dose. Short-course studies often excluded severe sepsis, catheters, immunocompromise, abscesses, CKD, prostatitis, complete obstruction and urinary surgery; individualize these cases and obtain source control. In sepsis with an obstructing stone, urgently drain the collecting system by ureteral stent or percutaneous nephrostomy while starting antibiotics, and delay definitive stone treatment until sepsis resolves .[50] Suspected acute bacterial prostatitis in febrile men may require longer treatment.[23]

EAU 2026 empirical IV options for systemic UTI : amoxicillin or a second-generation cephalosporin plus an aminoglycoside, or a third-generation cephalosporin. Use ciprofloxacin only when local resistance is below 10% and the patient cannot receive a third-generation cephalosporin or an aminoglycoside, or is hypersensitive to beta-lactams. Avoid fluoroquinolones empirically in urology-department patients or after fluoroquinolone use in the previous six months, cover ESBL when the likelihood is raised, and correct the urologic abnormality.[30]

ESBL-Producing Enterobacterales​

IDSA 2026 separates bladder infection from cUTI. For susceptible ESBL cystitis, options include nitrofurantoin, TMP-SMX, pivmecillinam, gepotidacin, sulopenem/probenecid and selected single-dose aminoglycoside therapy. Oral fosfomycin is an alternative for E. coli, not a reliable choice for Klebsiella.[8]

For ESBL cUTI, IDSA 2026 prefers susceptible TMP-SMX or fluoroquinolones; cefepime/enmetazobactam or a carbapenem becomes preferred when resistance, intolerance or toxicity precludes those agents. The 2026 guidance also discusses IV fosfomycin and aminoglycosides as alternatives in selected cases; piperacillin/tazobactam is an alternative for ESBL cUTI only in patients without critical illness or concomitant bacteremia.[8] Oral and IV fosfomycin are not interchangeable; oral fosfomycin is not initial pyelonephritis therapy. For selected clinically improving patients with ESBL-producing E. coli cUTI when other suitable oral options are unavailable, IDSA 2026 considers multidose oral fosfomycin for IV-to-oral transition but does not prefer it.[8] A 2026 randomized trial of 299 adults (152 oral, 147 IV) with ESBL-producing Enterobacterales cUTI who improved after 3–7 IV days found clinical cure within four days after treatment completion in 92.8% with oral fosfomycin 3 g daily versus 95.2% with continued IV therapy.[8][39]

Difficult-to-Treat Resistant (DTR) Pseudomonas​

Use susceptibility-guided ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/cilastatin/relebactam or cefiderocol for cUTI; cefiderocol is favored for metallo-β-lactamase-producing strains.[8]

Carbapenem-Resistant Enterobacterales (CRE)​

Determine the carbapenemase mechanism and susceptibility. KPC commonly directs selection toward meropenem/vaborbactam, ceftazidime/avibactam or imipenem/relebactam; OXA-48-like enzymes favor ceftazidime/avibactam. For invasive NDM infections, IDSA 2026 prefers aztreonam/avibactam or cefiderocol; ceftazidime/avibactam plus aztreonam is an alternative when the fixed combination is unavailable.[8]

Acute Bacterial Prostatitis​

Acute bacterial prostatitis commonly involves E. coli, Klebsiella, Proteus and Pseudomonas; after transurethral manipulation, suspected Pseudomonas warrants an antipseudomonal agent rather than ceftriaxone.[12][13][41]

Diagnostic and procedural checks: Obtain a midstream urine culture to guide treatment , and do not perform prostatic massage .[30]

IV empiric:

  • Piperacillin-tazobactam
  • Ceftriaxone
  • Fluoroquinolones (ciprofloxacin / levofloxacin)

Oral step-down:[41]

  • Ciprofloxacin 500 mg PO BID
  • Levofloxacin 500–750 mg PO daily[41]
  • TMP-SMX 160/800 mg PO BID[41]

Duration: 2–4 weeks total across IV and oral therapy, when both are used; EAU 2026 treats acute prostatitis under its systemic-UTI recommendations (evidence LE 3, uncontrolled studies).[30] Individualize duration and drain an abscess or relieve obstruction when indicated.[12]

Chronic Bacterial Prostatitis​

Requires antibiotics that penetrate prostatic tissue (lipophilic, low protein binding).[12][14]

First-line (minimum 4 weeks):[30][13]

  • Ciprofloxacin 500 mg PO BID
  • Levofloxacin 500 mg PO daily[46]

EAU 2026 also recommends a fluoroquinolone first (Strong; a systematic review found no significant differences among levofloxacin, ciprofloxacin and prulifloxacin in microbiological eradication, clinical efficacy or adverse events) for 4–6 weeks.[30]

Alternatives must be pathogen directed: TMP-SMX may be used for a susceptible organism.[30] Doxycycline is chiefly for identified intracellular pathogens: EAU 2026 gives doxycycline 100 mg BID for 10 days for Chlamydia trachomatis or mycoplasma, azithromycin 500 mg daily for up to 3 weeks only for C. trachomatis, and metronidazole 500 mg TID for 14 days for T. vaginalis (all Strong).[30] The guideline text is internally inconsistent on duration: it states at least 14 days for a fluoroquinolone and at least 3 to 4 weeks for azithromycin or doxycycline, whereas its regimen table lists the shorter doxycycline and azithromycin courses above.[30] Multidose oral fosfomycin is an off-label specialist option in selected resistant cases; the duration and initial daily phase differ from single-dose cystitis treatment.[14]

Catheter-Associated UTI (CAUTI)​

  • EAU 2026: treat symptomatic CAUTI as localized or systemic UTI ; obtain a culture before antimicrobials from a freshly placed catheter if catheterization continues; if catheterization ends, obtain a urine culture before antimicrobials from a voided midstream specimen; replace or remove the indwelling catheter before starting antimicrobials [30]
  • Remove an unnecessary catheter; replace a still-needed catheter present >2 weeks and obtain a fresh specimen, without delaying urgent therapy in sepsis
  • Treatment duration: the EAU 2026 guideline recommends 7 days when symptoms resolve promptly and 14 days when the response is delayed, whether or not the catheter stays in.[30] A 5-day levofloxacin course may be considered in patients who are not severely ill, and 3 days in women aged 65 or younger without upper-tract symptoms after catheter removal. In a spinal-cord-injury trial (61 enrolled; 55 analyzed), five days with catheter exchange met noninferiority for end-of-therapy clinical cure versus 10 days with catheter retention (55/55 cured); recurrence was higher after the shorter course.[42] Long-term indwelling catheters are not changed routinely.[30]
  • Diagnose CAUTI from new or worsening compatible symptoms and urine culture; cloudy or malodorous urine and pyuria alone do not distinguish CAUTI from catheter-associated asymptomatic bacteriuria. Select treatment by organism susceptibility and local resistance.[30]

Asymptomatic Bacteriuria — When NOT to Treat​

In spinal cord injury, new leakage, spasticity, autonomic dysreflexia or malaise with bacteriuria and pyuria may indicate symptomatic UTI despite absent dysuria; assess change from baseline and other causes.[11]

Per IDSA 2019 ASB guideline:[11]

  • Do not treat in healthy non-pregnant women, older adults (community-dwelling with functional impairment, or in long-term care), diabetic patients, spinal cord injury patients, catheter carriers (short- or long-term) or patients with implanted urologic devices solely because a culture is positive. For continent diversions, augmentations and other dysfunctional or reconstructed lower urinary tracts, EAU 2026 recommends against screening or treating ASB .[30]
  • Treat in pregnancy and before endoscopic urologic procedures with mucosal trauma; kidney transplantation is not a blanket indication to eradicate ASB. Evidence in the first month after transplant is insufficient; later routine treatment is not recommended
  • Early renal transplant is contested: the AUGS 2025 consensus statement (Q9) favors treating ASB in women within 2 months of a renal transplant[35], whereas EAU 2026 recommends against screening for or treating ASB in renal transplant recipients , citing RCTs that included the first 2 months (numerically more UTI and pyelonephritis with treatment).[30] Both advise against routine treatment later.[30][35]

Dosing & Administration​

Doses listed are for reference only. Confirm with current guidelines and institutional protocols. All doses assume normal renal function; adjust for CKD per package labeling.

Renal function checkpoints from US labels and guidelines:

AgentRenal rule
NitrofurantoinMacrobid label: contraindicated at CrCl <60 mL/min; EAU 2026: contraindicated at eGFR <30; WikiGuidelines: may use to CrCl 30 mL/min[7][30][31]
Most agents (EAU 2026, renal insufficiency)In its cystitis section, EAU states that most antimicrobials have a wide therapeutic index and gives a general dose-adjustment threshold of GFR <20 mL/min, except for nephrotoxic agents such as aminoglycosides. Agent-specific US labels require earlier adjustment: Zaynich and Utebzi below eGFR 60 and Contepo at CrCl 50 or lower. Follow the selected agent's label. EAU cautions that a loop diuretic with a cephalosporin is nephrotoxic. For perioperative prophylaxis, EAU allows gentamicin when skin-wound infection risk is low and eGFR is above 20 mL/min. The guideline gives no strength rating for these statements.[26][27][28][30]
TMP-SMXCrCl >30 usual dose; 15–30 half the usual regimen; <15 not recommended
Levofloxacin 750 mg dailyCrCl 20–49: 750 mg every 48 h; 10–19 or dialysis: 750 mg once, then 500 mg every 48 h[44]
PivmecillinamNo adjustment suggested by the label[17]
GepotidacinAvoid at eGFR <30[25]
Sulopenem/probenecidNot recommended at CrCl <15 or on hemodialysis[29]
Ciprofloxacin, aminoglycosidesAdjust per label and levels
SyndromeRegimenDuration
Uncomplicated cystitisNitrofurantoin monohydrate/macrocrystals 100 mg BID[30]5 days
TMP-SMX 160/800 mg BID[30]3 days
Fosfomycin 3 g1 dose
Pyelonephritis (PO)Ciprofloxacin 500 mg BID[30]Usually 7 days in improving patients
Levofloxacin 750 mg daily[45]5 days
TMP-SMX 160/800 mg BID (if susceptible)[30][23]See IDSA 2025 duration/exclusions above
Pyelonephritis initial IVCeftriaxone 1–2 g daily→ PO when improving
cUTI / urosepsisEffective agent by severity and susceptibilitySee short-course criteria/exclusions above; bacteremia alone does not mandate extension
Gram-negative bacteremia of urinary sourceEffective systemic therapy; selected oral step-downOften 7 days with clinical response and source control
Acute bacterial prostatitisIV pip-tazo or ceftriaxone → PO fluoroquinolone or TMP-SMX2–4 weeks
Chronic bacterial prostatitisCiprofloxacin 500 mg BID or levofloxacin 500 mg daily[46]Minimum 4 weeks[30]
Alternative (chronic bacterial prostatitis)Pathogen-directed specialist regimenAgent- and organism-specific

High-dose oral β-lactam step-down (bacteremia of urinary origin)​

Examples used in selected susceptible urinary-source gram-negative bacteremia after stabilization and source control; IDSA notes that oral β-lactam evidence is more limited:[6]

  • Amoxicillin 1000 mg PO q8h[47]
  • Amoxicillin-clavulanate 875/125 mg PO q8h[6][47]
  • Cephalexin 1000 mg PO q6h[47]

Confirm organism and MIC, renal dosing and absorption with pharmacy.

Contraindications & Precautions​

Nitrofurantoin​

  • Renal restriction: EAU guidance contraindicates nitrofurantoin at eGFR <30 mL/min/1.73 m²; Beers advises avoidance at CrCl <30 mL/min in older adults; US Macrobid labeling still lists CrCl <60 mL/min as a contraindication.[30][31] Follow the applicable local policy and distinguish guidance from labeling; avoid use for pyelonephritis or suspected prostatitis.[30][31]
  • Late pregnancy (≥38 weeks). Neonatal hemolysis risk
  • G6PD deficiency. Hemolysis
  • Long-term use. Pulmonary fibrosis, peripheral neuropathy, chronic hepatitis

TMP-SMX​

  • Sulfa allergy
  • G6PD deficiency
  • Late pregnancy. Kernicterus risk
  • Hyperkalemia, renal impairment. Potassium and creatinine changes
  • Drug interactions: warfarin (raised INR), methotrexate, phenytoin, ACEi and ARBs (hyperkalemia)

Fluoroquinolones​

  • Boxed/major warnings: tendon injury, peripheral neuropathy, CNS effects and worsening myasthenia gravis; aortic aneurysm/dissection and dysglycemia are additional serious warnings, not all part of the boxed warning.[34]
  • QT prolongation. Torsade risk with other QT-prolonging drugs
  • Avoid in pregnancy (limited data; animal evidence of cartilage damage)
  • Avoid in patients <18 years except specific indications

Aminoglycosides​

  • Nephrotoxicity. Monitor creatinine
  • Ototoxicity. Particularly in elderly; monitor audiometry in prolonged courses
  • Neuromuscular blockade. Avoid with neuromuscular disease
  • Loading dose plus extended interval. Preferred over traditional q8h dosing for efficacy and toxicity profile

Carbapenems​

  • Cross-reactivity with penicillin allergy. In 1,127 patients with skin-test- or drug-provocation-confirmed IgE- or T-cell-mediated penicillin allergy, pooled cross-reactivity to any carbapenem was 0.87% (95% CI 0.32–2.32%).[40]
  • Seizure risk at high doses or in renal failure (imipenem highest)
  • Reserve for resistant organisms. Stewardship imperative

Resistance Considerations​

Species, syndrome, setting and sampling year alter the estimate; use a recent, relevant local antibiogram and the patient's prior isolates.[15]

Local antibiogram guidance​

Use local antibiogram data to guide empiric therapy. Resistance varies substantially by:

  • Geographic region
  • Hospital versus community
  • Patient population (catheter, transplant, neurogenic)
  • Prior antibiotic exposure: <90 days raises resistance risk; for empiric fluoroquinolones in cUTI, IDSA 2025 suggests avoiding the class after exposure within 12 months (conditional; very low certainty).[6]

In a randomized vignette survey, both traditional and syndromic antibiograms improved simulated prescribing compared with no tool; the two formats performed similarly overall.[16]

Stewardship principles​

  • Shortest effective duration. Short-course regimens match longer ones for cystitis
  • De-escalate when susceptibility data return
  • Step-down to oral when clinically improving
  • Reserve carbapenems for MDR organisms
  • Do NOT treat asymptomatic bacteriuria outside specific indications

Perioperative Considerations​

Before urologic procedures with mucosal trauma​

Per IDSA 2019 ASB guideline:[11]

  • Screen and treat asymptomatic bacteriuria before endoscopic procedures with mucosal disruption (e.g., TURP, URS and PCNL)
  • 1–2 doses of targeted antimicrobial therapy based on urine culture susceptibility
  • Start 30 to 60 minutes before the procedure (IDSA). ASHP allows up to 120 minutes for vancomycin or fluoroquinolones; see Perioperative Antibiotic Prophylaxis
  • The AUA best practice statement takes a more pragmatic view: standard single-dose prophylaxis, chosen from prior cultures or the local antibiogram, is given whether or not ASB is present, and a separate pre-procedure treatment course is not required[10]

For full perioperative framework including non-ASB prophylaxis,[10] see Perioperative Antibiotic Prophylaxis.

Post-reconstructive patients with persistent bacteriuria​

  • Continent diversions (Mitrofanoff, Indiana pouch, neobladder). Frequently colonized; do not treat asymptomatic colonization
  • Augmentation cystoplasty. Similar; mucus and bacteriuria are expected
  • IPP, AUS. Investigate symptomatic infection promptly. IDSA suggests no routine ASB screening or treatment solely for implantation, while standard perioperative prophylaxis remains indicated.[11]

Evidence and practical interpretation​

Short-course cystitis regimens have randomized evidence.[30] IDSA 2025 grades cUTI duration and oral transition recommendations conditionally, with important exclusions.[6][22][23][6][22][23]

  • EAGLE-2/3 compared gepotidacin with nitrofurantoin; Pivya's approval evidence used different comparators.[18][17]
  • CERTAIN-1's primary comparison concerned organisms susceptible to both study drugs.[20]
  • Do not prescribe antibiotics for asymptomatic colonization outside the established exceptions above.
  • For CP/CPPS or CSCP, AUA 2025 advises against repeated antimicrobial courses with negative urine cultures, negative STI tests, or after vasectomy . In antibiotic-naive CSCP, it permits one 10-day antimicrobial trial . Pelvic-floor symptoms can favor foregoing antibiotics, and post-vasectomy pain does not need empiric antibiotics.[38]

Newer US approvals: distinct indications​

DrugLabeled role and key prescribing limits
Sulopenem etzadroxil/probenecid (Orlynvah, 2024)FDA-labeled for adult female uncomplicated UTI with limited/no alternative oral options: one 500 mg/500 mg tablet twice daily for 5 days; the label states it is not indicated for cUTI or step-down after IV cUTI therapy.[29] IDSA 2026 suggests off-label oral sulopenem as an alternative for selected ESBL-E cUTI only after initial clinical improvement, but does not suggest it for ESBL-E bloodstream-infection transition.[8] Check β-lactam allergy, uric-acid stones, blood dyscrasias and the contraindicated ketorolac interaction.[29]
IV fosfomycin (Contepo, October 2025)Adult cUTI including pyelonephritis from susceptible E. coli/K. pneumoniae; separate from oral fosfomycin. Label: 6 g IV every 8 hours over 1 hour for up to 14 days with normal renal function; dose-reduce below CrCl 50. Each vial carries about 1,980 mg sodium (hypernatremia, hypokalemia, fluid overload risk); avoid with QT prolongation; monitor serum electrolytes and fluid status, liver enzymes, and neutrophil counts.[28]
Cefepime/zidebactam (Zaynich, May 2026)Adult cUTI including pyelonephritis from designated susceptible organisms. Label: 3 g IV every 8 hours over 1 hour for 7–10 days when eGFR ≥60; reduce with renal impairment and monitor for cefepime neurotoxicity.[27]
Tebipenem pivoxil (Utebzi, June 2026)Oral carbapenem for adult cUTI including pyelonephritis caused by susceptible E. coli, K. pneumoniae, K. oxytoca, E. cloacae complex or E. faecalis when alternative oral options are limited or unavailable. Label: 600 mg every 6 hours for 7–10 days at eGFR 60–150; use the separate renal schedules below 60, and it is not recommended above 150. Do not extend courses beyond labeling; carnitine deficiency and β-lactam hypersensitivity are contraindications, and concomitant valproate should be avoided.[26]

Pivya: the US label is 185 mg pivmecillinam (equivalent to 200 mg pivmecillinam hydrochloride) TID for 3–7 days.[17] European and IDSA AMR dosing discussions include higher off-label regimens; do not present 400 mg TID as the US Pivya label.[8][17][30] Check serious β-lactam hypersensitivity, carnitine deficiency and acute porphyria; avoid concurrent valproate or other pivalate-generating drugs because of carnitine depletion.[17][8]

Blujepa: for female uUTI at age ≥12 and weight ≥40 kg, 1,500 mg BID for five days after meals. Review QT risk, interacting CYP3A drugs, and severe renal or hepatic impairment; during anesthesia, gepotidacin may prolong succinylcholine-induced neuromuscular blockade; use the UTI schedule rather than the separate gonorrhea regimen.[25]

See Also​

References​

1. Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians. Ann Intern Med. 2021;174(6):822–827. doi:10.7326/M20-7355

2. Dakkak M, Sabharwal M. Antibiotic courses for common infections: recommendations from the ACP. Am Fam Physician. 2022;105(2):205–206. PMID 35166486

3. Kurotschka PK, Gágyor I, Ebell MH. Acute uncomplicated UTIs in adults: rapid evidence review. Am Fam Physician. 2024;109(2):167–174. PMID 38393801

4. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–84. doi:10.1001/jama.2014.12842

5. Johnson JR, Russo TA. Acute pyelonephritis in adults. N Engl J Med. 2018;378(1):48–59. doi:10.1056/NEJMcp1702758

6. Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated urinary tract infections: selection of antibiotic therapy for complicated UTI. Infectious Diseases Society of America; 2025. Current IDSA guideline and manuscripts.

7. Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement. JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

8. Tamma PD, Bonomo RA, Heil EL, Justo JA, Satlin MJ, Mathers AJ. IDSA 2026 guidance on treatment of antimicrobial-resistant gram-negative infections. Current web guidance accessed September 12, 2026; supersedes the 2024 edition.

9. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023;ciad428. doi:10.1093/cid/ciad428

10. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351–356. doi:10.1097/JU.0000000000000509

11. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

12. Borgert BJ, Wallen EM, Pham MN. Prostatitis. JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

13. Lam JC, Stokes W. Acute and chronic prostatitis. Am Fam Physician. 2024;110(1):45–51. PMID 39028781

14. Lam JC, Lang R, Stokes W. How I manage bacterial prostatitis. Clin Microbiol Infect. 2023;29(1):32–37. doi:10.1016/j.cmi.2022.05.035

15. Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated urinary tract infections: introduction and methods. Infectious Diseases Society of America; 2025. Current IDSA guideline and manuscripts.

16. Taylor LN, Wilson BM, Singh M, et al. Syndromic antibiograms and nursing home clinicians' antibiotic choices for urinary tract infections. JAMA Netw Open. 2023;6(12):e2349544. doi:10.1001/jamanetworkopen.2023.49544

17. US Food and Drug Administration/Alembic. Pivya prescribing information. Revised October 2025; accessed September 12, 2026.

18. Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741–755. doi:10.1016/S0140-6736(23)02196-7

19. Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304–1314. doi:10.1001/jama.2022.17034

20. Wagenlehner FM, Gasink LB, McGovern PC, et al. Cefepime–taniborbactam in complicated urinary tract infection. N Engl J Med. 2024;390(7):611–622. doi:10.1056/NEJMoa2304748

21. Kim DK, Kim JH, Lee JY, et al. Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials. Lancet Infect Dis. 2020;20(9):1080–1088. doi:10.1016/S1473-3099(20)30121-3

22. Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated urinary tract infections: timing of intravenous-to-oral antibiotic transition. Infectious Diseases Society of America; 2025. Current IDSA guideline and manuscripts.

23. Trautner BW, Cortés-Penfield NW, Gupta K, et al. IDSA 2025 guideline on management and treatment of complicated urinary tract infections: duration of antibiotics for complicated UTI. Infectious Diseases Society of America; 2025. Current IDSA guideline and manuscripts.

24. AUA/CUA/SUFU. Recurrent uncomplicated urinary tract infections in women guideline. Amended 2025.

25. GSK. Blujepa US prescribing information. Revised February 2026.

26. FDA. Utebzi prescribing information. June 2026.

27. FDA. Zaynich prescribing information. May 2026.

28. FDA. Contepo prescribing information. October 2025.

29. FDA. Orlynvah approval and prescribing limits. October 2024.

30. EAU. Guidelines on urological infections. 2026 (limited update March 2026); sections 3.4 cystitis, 3.5 recurrent cystitis, 3.6 pyelonephritis, 3.7 systemic UTI, 3.8 CA-UTI, 3.11 prostatitis and 3.18 prophylaxis. Full guideline.

31. Macrobid US prescribing information; American Geriatrics Society. 2023 updated Beers Criteria. doi:10.1111/jgs.18372.

32. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women. JAMA. 2018;319:1781–1789. doi:10.1001/jama.2018.3627.

33. Canadian Society of Allergy and Clinical Immunology. Practical guide for evaluation and management of beta-lactam allergy. 2020 position statement.

34. FDA. Fluoroquinolone safety communication: aortic risks and related major warnings. December 2018.

35. Siddiqui NY, Ackerman AL, Advani SD, et al. "Management of Asymptomatic Bacteriuria in Adult Female Populations." Urogynecology (Phila). 2025;31(9):827–845. doi:10.1097/SPV.0000000000001731

36. Lafaurie M, Bruyère F, Boutfol W, et al. Updated guidelines for management of community-acquired urinary tract infections in adult men by the French infectious disease society (SPILF). Infect Dis Now. 2026;56(6S):105312. doi:10.1016/j.idnow.2026.105312

37. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation. J Urol. 2026;216(2):143–151. doi:10.1097/JU.0000000000005097

38. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part III Treatment of Chronic Scrotal Content Pain. J Urol. 2025;214(2):138-146. doi:10.1097/JU.0000000000004566 See also Part II. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Urol. 2025;214(2):127-137. doi:10.1097/JU.0000000000004565 Full 2025 guideline

39. Seo JW, Kim DY, Yoon Y, et al. "Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial." Clin Infect Dis. Published online June 18, 2026. doi:10.1093/cid/ciag345

40. Picard M, et al. "Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses." J Allergy Clin Immunol Pract. 2019;7(8):2722–2738.e5. doi:10.1016/j.jaip.2019.05.038

41. Coker TJ, Dierfeldt DM. "Acute Bacterial Prostatitis: Diagnosis and Management." Am Fam Physician. 2016;93(2):114–120. PMID:26926407.

42. Darouiche RO, Al Mohajer M, Siddiq DM, Minard CG. "Short Versus Long Course of Antibiotics for Catheter-Associated Urinary Tract Infections in Patients With Spinal Cord Injury: A Randomized Controlled Noninferiority Trial." Arch Phys Med Rehabil. 2014;95(2):290–296. doi:10.1016/j.apmr.2013.09.003

43. RedPharm Drug, Inc. Levofloxacin tablets: US prescribing information. DailyMed; sections 2.1, 2.3, 14.6. Label.

44. RedPharm Drug, Inc. Levofloxacin tablets: US prescribing information. DailyMed; sections 2.1, 2.3, 14.6. Label.

45. RedPharm Drug, Inc. Levofloxacin tablets: US prescribing information. DailyMed; sections 2.1, 2.3, 14.6. Label.

46. RedPharm Drug, Inc. Levofloxacin tablets: US prescribing information. DailyMed; sections 2.1, 2.3, 14.6. Label.

47. Heil EL, Bork JT, Abbo LM, et al. "Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process." Open Forum Infect Dis. 2021;8(10):ofab434. doi:10.1093/ofid/ofab434

48. Cipla USA, Inc. Zemdri (plazomicin) injection: US prescribing information. Revised February 2023. DailyMed.

49. Lafaurie M, Chevret S, Fontaine JP, et al. "Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial." Clin Infect Dis. 2023;76(12):2154–2162. doi:10.1093/cid/ciad070

50. EAU Guidelines Office. "EAU Guidelines on Urolithiasis." 2026. Full guideline.